menu
    • menu
    [{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antisense oligonucleotides","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Sun Yat-sen University","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Pharma \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Antisense OligoNucleotides","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vico Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Vico Therapeutics \/ Life Science Partners","highestDevelopmentStatusID":"4","companyTruncated":"Vico Therapeutics \/ Life Science Partners"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Antisense Oligonucleotides","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Secarna","highestDevelopmentStatusID":"3","companyTruncated":"Denali Therapeutics \/ Secarna"},{"orgOrder":0,"company":"Biorchestra","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antisense Oligonucleotides","moa":"microRNAs","graph1":"Neurology","graph2":"Discovery","graph3":"Biorchestra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biorchestra \/ SK Biopharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Biorchestra \/ SK Biopharmaceutical"},{"orgOrder":0,"company":"Argonaut Manufacturing Services","sponsor":"n-Lorem Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotides","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Argonaut Manufacturing Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Argonaut Manufacturing Services \/ n-Lorem Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Argonaut Manufacturing Services \/ n-Lorem Foundation"},{"orgOrder":0,"company":"AUM LifeTech","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Antisense Oligonucleotides","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM LifeTech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM LifeTech \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"AUM LifeTech \/ National Cancer Institute"}]

    Find Clinical Drug Pipeline Developments & Deals for Antisense Oligonucleotides

    Menu

    Antisense Oligonucleotides

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AUM LifeTech

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            AUM LifeTech

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : National Cancer Institute

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Philadelphia-based Biotech Company AUM LifeTech Awarded $400,000 NCI/NIH Grant to Advance Their Lung Cancer Im...

                            Details : AUM LifeTech's FANA Antisense Oligonucleotide (FANA ASO) RNA silencing approach allows efficient and selective targeting of human FOXP3 at the RNA level, in a highly sequence-specific manner.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 17, 2022

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : National Cancer Institute

                            Deal Size : $0.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Argonaut Manufacturing Services

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Argonaut Manufacturing Services

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : n-Lorem Foundation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            n-Lorem Foundation Partners with Argonaut to Manufacture ASO Medicines for Patients with Nano-rare Diseases

                            Details : The partnership will supports and reduces the cost of manufacturing of n-Lorem’s experimental antisense oligonucleotide (ASO) medicines developed for nano-rare disease patients (1 to 30 patients worldwide) for free, for life.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 02, 2022

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : n-Lorem Foundation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biorchestra

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Biorchestra

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SK Biopharmaceuticals, BIORCHESTRA Collaborate to Develop miRNA-Targeted Therapeutics

                            Details : Under the collaboration agreement, BIORCHESTRA, that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology by using antisense oligonucleotides.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 05, 2022

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Denali Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Denali Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Secarna Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development...

                            Details : As part of the collaboration, Secarna will employ its commercially validated discovery and development platform, LNAplus™ to generate antisense oligonucleotide candidates against targets relevant for the treatment of neurodegenerative diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 26, 2021

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Secarna Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vico Therapeutics

                            Netherlands arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Vico Therapeutics

                            Netherlands arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Life Science Partners

                            Deal Size : $31.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Vico Therapeutics Raises $31 Million in Series A Financing Round

                            Details : Vico will use this funding to further advance its late preclinical stage Antisense OligoNucleotides lead platform for the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinica...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 30, 2020

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Life Science Partners

                            Deal Size : $31.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Secarna Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Secarna Pharma

                            Germany arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Sun Yat-sen University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Secarna Pharmaceuticals Enters into Cooperation with Guangzhou’s Sun Yat-sen University to Develop a Treatme...

                            Details : Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 28, 2020

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Sun Yat-sen University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth